

Table 1: Subgroup Analyses for oral oseltamivir versus no antiviral therapy

Outcome	Confirmed influenza	Age	Pregnant women (50)	Baseline risk	Dose	Influenza A or B	Pandemic/ Seasonal	Severity of Influenza	Funding Conflict
Mortality	NS	NS	OR 0.64 (0.23 to 1.74)	Immunocompromised (13) OR 0.03 (0 to 0.69)	-	-	Pandemic: OR 0.93 (0.47 to 1.84) Seasonal: OR 0.29 (0.17 to 0.52) p = 0.01	Hospitalized versus ICU patients: NS	-
Hospitalization	NS	NS	OR 1.44 (0.87 to 2.39)	Diabetes (44) OR 0.59 (0.44 to 0.78)	-	-	-	-	Conflict in largest studies
ICU admission/ Ventilation/ Respiratory failure	-	-	OR 0.69 (0.37 to 1.28)	-	-	-	-	-	-
Time to alleviation of symptoms	-	-	-	-	-	A: SMD -0.66 (-0.81 to -0.50) B: SMD -0.56 (-0.67 to -0.44) p < 0.03	-	-	-
Complications Pneumonia	Confirmed OR 0.15 (0.05, 0.46) Unconfirmed OR 0.70 (0.51, 0.96) P = 0.01	Children: OR 0.71 (0.60 to 0.85) Adults: OR 1.05 (0.96 to 1.15) ≥65: OR 1.35 (0.98 to 1.87) P < 0.0001	-	2 studies OR 0.38 (0.07 to 1.95)	-	-	-	-	Conflict in largest studies
Complications Otitis media	-	Children: OR 0.73 (0.67 to 0.80), Adults: OR 0.93 (0.83 to 1.04) ≥65: OR 0.51 (0.14 to 1.90) p < 0.005	-	Diabetes (44) OR 1.06 (0.54 to 2.06)	-	-	-	-	Conflict in largest studies

“-” indicates insufficient data to test for subgroup interactions; NS indicates non significant interaction